Search

Your search keyword '"Karissa Finke"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Karissa Finke" Remove constraint Author: "Karissa Finke"
21 results on '"Karissa Finke"'

Search Results

1. Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer

2. Supplementary section from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

3. Figure S1 from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

4. Data from Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

5. Data from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

6. Supplementary Figure 2 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

7. Supplementary Figure 3 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

8. Supplementary Figure 1 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

9. Abstract P4-10-03: Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer

10. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

11. Abstract P2-08-16: Impact of germline BRCA mutation status on survival in women with metastatic triple negative breast cancer

12. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

14. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1)

15. Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC)

16. Abstract PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer

17. Impact of Germline BRCA Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer

18. LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates

19. LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs

20. Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer

21. Comparison of outcomes for AJCC 8th Anatomic and Prognostic staging in contemporary triple negative breast cancer (TNBC) multisite registry

Catalog

Books, media, physical & digital resources